BioXyTran Inc
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
75 2nd Ave Ste 605, Needham, Massachuset...Phone Number
(617) 454-1199Website
www.bioxytraninc.comRevenue
<$5 MillionStock Symbol
BIXTIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BioXyTran Inc
Based in Newton, MA, Bioxytran Inc. is a developmental stage biopharmaceutical company developing anti-necrosis drugs that treat hypoxia by delivering oxygen. Hypoxia, a condition resulting in an insufficient supply of oxygen to bodily tissues, causes a variety of severe, harmful medical conditions including cancer growth. The company is focusing on the development and commercialization of first-in-class treatments to prevent brain damage resulting from hypoxic conditions following brain stroke and trauma. The Company's lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat ischemic brain strokes, caused by severely reduced blood flow to the brain. In addition, the company plan to test another drug candidate, BXT-252, as a resuscitative agent in a variety of wound-healing applications, as well as in organ transplantation and cancer contexts.Explore more
BioXyTran Inc Org Chart
LA
Chief Marketing Officer
AA
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioXyTran Inc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if BioXyTran Inc is spiking on competitors!
Funding: Get notified immidiatlly once BioXyTran Inc has new funding data
Earning: See what the market has to say on BioXyTran Inc recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioXyTran Inc
Check if BioXyTran Inc has recently received funding, and reach out quickly before it becomes old news!
BioXyTran Inc, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if BioXyTran Inc had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when BioXyTran Inc launches new products
Recommended Actions
Find VP level buyers at BioXyTran Inc
Find 3 more new buyers
Compare Similar Companies to BioXyTran Inc
Compare insights from companies similar to BioXyTran Inc, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioXyTran Inc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioXyTran Inc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioXyTran Inc.
BioXyTran Inc financials insights
Gather financial insights about BioXyTran Inc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Other Financing Round
$1.6M
2026
Stock/Share Issuance
$1.2M
BioXyTran Inc Tech Stack
A closer look at the technologies used by BioXyTran Inc
Most Recent Scoops
Funding
Funding
Project
Research & Development, Medical Research, Pharmaceuticals
Person-Based
Person-Based
Person-Based
BioXyTran Inc News & Media
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
Financing strengthens balance sheet and supports advancement of key development initiativesBioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected OutpatientsBioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
BOSTON, MA, Feb 23, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu. The collaboration follows a previously announced Non-Disclosure AgreemenBioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
BOSTON, MA, Feb 17, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCMKTS: BIXT) (“Bioxytran” or the “Company”), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD (“Khoury Medical”), a company focused on the development and commercialization of plant-derived dietary supplements. Under the agr
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioXyTran Inc
Sign Up For FreeTo access detailed company insights
Based in Newton, MA, Bioxytran Inc. is a developmental stage biopharmaceutical company developing anti-necrosis drugs that treat hypoxia by delivering oxygen. Hypoxia, a condition resulting in an insufficient supply of oxygen to bodily tissues, causes a variety of severe, harmful medical conditions including cancer growth. The company is focusing o... Read More
